Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 4von Hippel-Lindau Disease 2Prostatic Neoplasms 2Meningioma 2Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Multiple Endocrine Neoplasia 1Medulloblastoma 1Hypoglycemia 1Hypertension 1Hyperparathyroidism 1Hypercalcemia 1Cancer Diagnosis 1Breast Neoplasms 1

Interventions

relacorilant 2pazopanib 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1fimasartan 1cediranib 1benazepril 1Surveys and Questionnaires 1Sulindac 1Ramipril 1Observation 1Losartan 1Lisinopril 1Interviews as Topic 1Hydrochlorothiazide 1Adrenalectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hypertension × gallium Ga 68 dotatate × Clear all
NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡